RARE Ultragenyx Pharmaceutical Inc.

Biotech Analyst Ratings

Latest News

1. 17 May 2022 Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics

   ABO-102 / UX111 is being evaluated in ongoing pivotal Transpher A trial in patients with MPS IIIA
   

   Interim data featured in encore oral presentation at American Society of Gene & Cell Therapy (ASGCT) today

   NOVATO, Calif. and NEW YORK and CLEVELAND, May 17, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced an exclusive license agreement for AAV gene therapy ABO-102 (now UX111) for the treatment of Sanfilippo syndrome type A (MPS IIIA). Under the terms of the agreement, Ultragenyx will assume responsibility for the ABO-102 program and in return Abeona is eligible to receive tiered royalties of up to 10% on net sales and commercial milestone payments following regulatory…

   View Full Article
2. 09 May 2022 Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting

   NOVATO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, today announced that clinical, preclinical and manufacturing data from its investigational gene therapy programs will be presented at the American Society of Gene & Cell Therapy (ASGCT) 25^th Annual Meeting, which will be held both in person and virtually May 16-19, 2022. The company will present new data supporting its gene therapy portfolio and discuss critical topics during a scientific symposium on Accelerated Approval and at the pre-meeting workshops.
   

   Clinical and pre-clinical presentations include:

   • Oral…

   View Full Article
3. 05 May 2022 Ultragenyx Reports First Quarter 2022 Financial Results and Corporate Update

   First quarter 2022 total revenue of $79.9 million and Crysvita® revenue in Ultragenyx territories¹ of $54.6 million
   

   Reaffirm 2022 Crysvita revenue in Ultragenyx territories guidance of $250 million to $260 million and Dojolvi revenue of $55 million to $65 million

   Cash balance of approximately $814 million as of March 31, 2022

   NOVATO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today reported its financial results for the quarter ended March 31, 2022 and reaffirmed its financial guidance for the year.

   "Product based revenue continues to grow driven by…

   View Full Article
4. 03 May 2022 Ultragenyx to Participate at BofA Securities 2022 Healthcare Conference

   NOVATO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Camille Bedrosian, M.D., the company's Chief Medical Officer, and Mardi Dier, the company's Chief Financial Officer, will present at the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, 2022 at 5:40 PM ET.
   

   The live and archived webcast of the presentation will be accessible from the company's website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.

   About Ultragenyx Pharmaceutical Inc.
   
   Ultragenyx is a biopharmaceutical company…

   View Full Article
5. 27 April 2022 Ultragenyx to Host Conference Call for First Quarter 2022 Financial Results and Corporate Update

   NOVATO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Thursday, May 5, 2022 at 5:00pm ET to discuss its financial results and corporate update for the quarter ended March 31, 2022.
   

   The live and replayed webcast of the call will be available through the company's website at https://ir.ultragenyx.com/events-presentations. To participate in the live call by phone, dial
   (855) 797-6910 (USA) or (262) 912-6260 (International) and enter the passcode 7951356. The replay of the call will be available for one…

   View Full Article